S&P 500
5.011,12 -11,09 (-0,22%) Nasdaq
15.601,50 -81,87 (-0,52%) NIKKEI 225
36.818,81 -1.260,89 (-3,31%) Dólar/Euro
1,0637 -0,0009 (-0,09%) Petróleo Brent
89,07 +1,96 (+2,25%) Bitcoin EUR
58.160,96 -173,52 (-0,30%)
AbbVie Inc. (ABBV)
Después del cierre:
AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
https://www.abbvie.com
Sector(es): Healthcare
Sector: Drug Manufacturers - General
Empleados a tiempo completo: 50.000
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Richard A. Gonzalez | Chairman & CEO | 7,19M | N/A | 1954 |
| Mr. Robert A. Michael | President & COO | 4,62M | N/A | 1970 |
| Mr. Scott T. Reents | Executive VP & CFO | 3,13M | N/A | 1968 |
| Dr. Azita Saleki-Gerhardt Ph.D. | Executive VP & COO | 3,51M | 5,25M | 1963 |
| Mr. Jeffrey Ryan Stewart | Executive VP & Chief Commercial Officer | 4,32M | 2,13M | 1969 |
| Dr. Thomas J. Hudson M.D. | Senior VP & Chief Scientific Officer of Global Research | N/A | N/A | 1962 |
| Ms. Elizabeth Shea | Senior Vice President of Investor Relations | N/A | N/A | N/A |
| Mr. Perry C. Siatis | Executive VP, General Counsel & Secretary | N/A | N/A | 1975 |
| Mr. Sanjay Narayan | Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal | N/A | N/A | N/A |
| Mr. Timothy J. Richmond | Executive VP & Chief Human Resources Officer | 1,12M | N/A | 1966 |
Descripción
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Gobierno corporativo
El ISS Governance QualityScore de AbbVie Inc., a día 1 de abril de 2024, es 8. Las puntuaciones base son Auditoría: 8; Tablero: 5; Derechos de los accionistas: 9; Compensación: 6.
